Genfit SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Genfit SA Announces Publication of GFT505-210-6 Clinical Study Data in Diabetes Care
Genfit SA announced the publication in Diabetes Care of data on the efficacy and mechanism of action of GFT505 on hepatic insulin resistance in man.The manuscript contains the data from the GFT505-210-6 clinical study showing that GFT505 increases the insulin sensitivity of the liver (+44%, p=0.006) and the other peripheral organs (+21%, p=0.048) in cardiometabolic patients.
Latest Developments for Genfit SA
- Genfit SA Announces Share Repurchase Program
- Genfit SA Announces Data Reporting the Efficacy and Mechanism of Action of GFT505 in Different Animal Models of NASH
- Genfit SA Announces Results of Phase II Clinical Studies Showing that GFT505 Reduces the Risk of Cardiovascular Events Through its Action on Remnant Cholesterol
- Genfit SA Raises Over EUR 14 Million via Capital Increase
- Share this
- Digg this